ClinicalTrials.gov
ClinicalTrials.gov Menu

Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00718744
Recruitment Status : Completed
First Posted : July 21, 2008
Last Update Posted : August 5, 2010
Sponsor:
Information provided by:
Laboratorios Leti, S.L.

Brief Summary:
The main purpose of the trial is to prove the therapeutic value of the product and enable an effective and safe dosage schedule to be recommended

Condition or disease Intervention/treatment Phase
Rhinitis, Allergic, Seasonal Conjunctivitis, Allergic Other: Standardization of allergenic extract (Ch. arcuatus) Phase 2

Detailed Description:
The skin testing procedure, based on the Nordic Guidelines is the reference method for the biological calibration of in-House Reference Preparations (IHRP). The method is not intended for routine testing of allergen extracts. The use of this procedure is the basis for the definition of biological activity units: "the activity of an allergen extract is 10,000 Biological Units (BU) per ml (10 HEP per ml), when the extract provokes an specific skin reaction in the median sensitive patient with a wheal of the same size as a wheal provoked by a positive reference solution consisting of histamine 54.3 mmol/l (for example histamine dihydrochloride 10 mg/ml), when both solutions are administrated using the same technique (prick testing) on at least 20 individuals who are clinically allergic and cutaneously reactive to the allergen concerned".

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units
Study Start Date : June 2008
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Arm Intervention/treatment
Experimental: A
In each individual patient, 10 mg/ml histamine dihydrochloride solution and a phenolated saline solution will be applied as positive and negative control respectively.
Other: Standardization of allergenic extract (Ch. arcuatus)
Allergenic extract for cutaneous prick-test



Primary Outcome Measures :
  1. Wheal size area (mm2) of the immediate phase reaction. [ Time Frame: 30 minutes per subject ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Voluntarily signed informed consent form by the patient
  • Patients should live in a geographic zone where allergy caused by Chortoglyphus arcuatus is a relevant problem.
  • Patients should not be excluded due to low or high sensitivity to the allergen, when they otherwise fulfil the inclusion criteria.
  • A positive case history with inhalant allergy related to exposure to the allergen to be tested.
  • A positive prick test (mean wheal diameter > 3 mm) when tested with a standardized extract prepared from the allergen source in question and/or a positive test for specific IgE.
  • A mean wheal diameter > 7 mm2 obtained in a prick test with histamine dihydrochloride 10 mg/ml.
  • Age: 18-50 years.
  • Both genders

Exclusion Criteria:

  • Immunotherapy in the past 2 years with an allergen preparation known to interfere with the allergens to be tested.
  • Use of drugs that may interfere with the skin reactions.
  • Pregnancy
  • Dermographism
  • Atopic dermatitis (locally at the test site)
  • Urticaria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00718744


Locations
Spain
Hospital "Xeral de Calde"
Calde, Lugo, Spain, 27004
Sponsors and Collaborators
Laboratorios Leti, S.L.
Investigators
Principal Investigator: Manuel Boquete, MD

Responsible Party: María José Gómez, Laboratorios LETI S.L.Unipersonal
ClinicalTrials.gov Identifier: NCT00718744     History of Changes
Other Study ID Numbers: 2005-001194-96
First Posted: July 21, 2008    Key Record Dates
Last Update Posted: August 5, 2010
Last Verified: August 2010

Keywords provided by Laboratorios Leti, S.L.:
Allergen-extract
Standardization

Additional relevant MeSH terms:
Rhinitis
Conjunctivitis
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Conjunctivitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Conjunctival Diseases
Eye Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases